全文获取类型
收费全文 | 369篇 |
免费 | 29篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 5篇 |
妇产科学 | 4篇 |
基础医学 | 31篇 |
口腔科学 | 32篇 |
临床医学 | 36篇 |
内科学 | 80篇 |
皮肤病学 | 6篇 |
神经病学 | 22篇 |
特种医学 | 13篇 |
外科学 | 54篇 |
综合类 | 31篇 |
预防医学 | 29篇 |
眼科学 | 12篇 |
药学 | 27篇 |
肿瘤学 | 10篇 |
出版年
2023年 | 13篇 |
2022年 | 45篇 |
2021年 | 48篇 |
2020年 | 26篇 |
2019年 | 38篇 |
2018年 | 33篇 |
2017年 | 24篇 |
2016年 | 18篇 |
2015年 | 20篇 |
2014年 | 26篇 |
2013年 | 22篇 |
2012年 | 19篇 |
2011年 | 19篇 |
2010年 | 8篇 |
2009年 | 7篇 |
2008年 | 8篇 |
2007年 | 10篇 |
2006年 | 6篇 |
2005年 | 5篇 |
2004年 | 1篇 |
2003年 | 3篇 |
2002年 | 1篇 |
1996年 | 1篇 |
1990年 | 1篇 |
1984年 | 1篇 |
排序方式: 共有403条查询结果,搜索用时 31 毫秒
1.
S.A. Alharbi F.F. Mahmoud A. Al AwAdi R.A. Al Jumma F. Khodakhast S.M. Alsulaiman 《International journal of immunogenetics》1996,23(1):67-70
This study is the first to assess the prevalence of HLA B27 in Kuwaiti patients with ankylosing spondylitis (AS) or related spondyloarthropathies compared to healthy controls. Positive HLA B27 was found in nine (25.7%) of 35 patients, but only in 22 (4%) of 544 controls (P = 0.000). A significant difference in Cw2 and Cw6 between patients and controls was also found (P < 0.01 and 0.000, respectively), suggesting a linkage disequilibrium between B27 and Cw2 (P < 0.000) in the Kuwaiti population. These findings suggest that B27-positive Kuwaitis are at high risk of developing AS and spondyloarthropathies, especially if they carry Cw2 and Cw6. The importance of HLA Cw loci is becoming increasingly apparent in disease association studies. 相似文献
2.
3.
Norah A. Alharbi Sadaga H. Alawi Yousef M. Alharbi Muath Y. Alharbi Tareq N. Alsamarh Adi A. Aldubaiyan Saleh A. Alwasil Abdulrahman A. Alomairi 《Neurosciences (Riyadh, Saudi Arabia)》2022,27(2):71
Objectives:To determine the prevalence of depression and anxiety in adult multiple sclerosis patients attending tertiary facilities in Riyadh, Saudi Arabia.Methods:This is a cross-sectional study conducted among MS patients in Riyadh City, Saudi Arabia. A self-administered questionnaire was distributed among MS patients at Prince Sultan Military Medical City in Riyadh, Saudi Arabia between April 2020 and January 2021. The questionnaire consisted of socio-demographic characteristics and the Hospital Anxiety and Depression Scale (HADS). Univariate using Chi-square test and multivariate regression analysis had been performed to determine the factors associated with anxiety and depression among MS patients.Results:A total of 328 MS patients took part in the study. The most prevalent age group was 36–45 years old (38.4%), with over 70% of the participants being females. Anxiety and depression were shown to be prevalent in MS patients at 42.9 percent and 58.8 percent, respectively. According to statistical tests, being less educated and having partial to severe disability was linked to an increased rate of anxiety and depression, whereas being female was more prone to anxiety symptoms but not depression.Conclusion:Depression was more frequent than anxiety. As a result, while assessing psychiatric diseases in the study group, depression/anxiety may be expected to be more frequent amongst those of greater disability. Multiple sclerosis (MS) is a central nervous system demyelinating disease caused by an immunological response. Depression and anxiety are more common in patients with multiple sclerosis (PWMS) than in the general population, 1-4 which is a well-known phenomenon. However, we believe that these illnesses are under-recognized in PWMS because several MS symptoms overlap with depression and anxiety, making detection more difficult. Fatigue, sleeplessness, anorexia, memory loss, and concentration problems are all common symptoms of depression, MS, or both. 5,6 Furthermore, the symptoms of MS might mislead self-report rating scales designed to detect depression and anxiety, resulting in false positives or negatives. 5,6 Moreover, depression in PWMS can impair their quality of life (QOL), medication adherence, and compliance, worsening their prognosis. 7-9 Suicidal thoughts and attempts are also common. 10-13 The hospital Anxiety and Depression Scale is a one-of-a-kind measure for detecting anxiety and depression while taking into account both disorders’ possible confounders, and it has been validated for use in PWMS. 6 Depression is a significant mood illness that affects many people. It creates severe symptoms that impact how you feel, think, and handle day-to-day tasks like working, sleeping, and eating. 14 In PWMS, the lifetime prevalence of depression in up to 50%, 3 compared to 10.8% in the general population. 15 The cause of depressive disorders in people with MS is unknown. However, it is assumed to be complex, with psychological, social, and neurological aspects - as well as immunologic and genetic factors - all having a part. 16 Furthermore, depression can have a severe impact on these patients’ health by raising the severity of their symptoms and reducing their compliance with therapy and follow-up, both of which have an impact on their medical costs. 9 In addition to a decreased quality of life (QOL), cognitive impairment, and an increased risk of suicide, especially when anxiety is present. 7,10,11 Furthermore, PWMS have a 10-year lower life expectancy than the general population of the same age. 2 Patients, caregivers, and care providers should not underestimate the impact of sadness and anxiety on PWMS. Improved identification, diagnosis, and treatment in medical offices, where people with mood disorders are frequently seen for the first time, can assist to improve these negative outcomes. 17 Unfortunately, despite convincing evidence of its high incidence, greater influence on prognosis, and quality of life, depression and anxiety are still underdiagnosed and undertreated. 13 The goal of this study is to find out how common depression and anxiety are among adult patients with multiple sclerosis in Riyadh, Saudi Arabia. We’ll also see if there’s a link between Hospital Anxiety and Depression Scale (HADS) score and patients’ demographical, socio-educational, and MS-related characteristics, as well as MS duration, Immunomodulatory type, and EDSS scores. 相似文献
4.
Jack Ogilvie Raymond Zhao Sandra Camelo-Piragua Mohannad Ibrahim Remy Lobo John Kim 《Radiology Case Reports》2022,17(8):2820
Amyloidomas are focal solitary amyloid masses without systemic involvement that have been observed to occur in various body locations. When presenting intracranially, they pose a challenging diagnostic and therapeutic course given their location and rarity. We report a case of a 62-year-old man with a 4-year history of seizure and headaches. Magnetic resonance imaging was initially inconclusive but revealed an ill-defined right temporal lobe lesion. Biopsy later confirmed a cerebral amyloidoma. We also review the current literature on the pathogenesis, imaging findings, prognosis, and treatment of cerebral amyloidomas. 相似文献
5.
6.
Ahmed Jamleh Mohannad Nassar Abdulmohsen Alfadley Azhar Alanazi Hadeel Alotiabi Maryam Alghilan Khalid Alfouzan 《Materials》2022,15(9)
This study assesses the retreatability of TotalFill bioceramic (TFBC) and AH Plus (AHP) sealers and their impact on retreatment force and torque. Twenty-six premolar teeth with single oval canals were instrumented, obturated using the matched gutta-percha cone technique with one of the tested sealers, and then temporized. After a 6-month incubation at 37 °C and 100% humidity, the canals were retreated with the XP Shaper system. During retreatment, the generated force and torque were measured. Micro-CT scanning was run before and after the retreatment procedure to analyze the remaining obturating materials in the canals. The apically directed maximum force in AHP was higher than that in TFBC. The coronally directed maximum force and the maximum torque were comparable between the groups. A higher amount of remaining obturating materials was found in the AHP compared to that in the TFBC. Based on these findings, endodontic sealer had an influence on retreatability, and the TFBC showed less remaining obturating materials and lower retreatment forces in the apical direction compared to the AHP in extracted teeth with oval canals. 相似文献
7.
8.
9.
Bryan D. Hayes Michael E. Winters Steve B. Rosenbaum Mohannad F. Allehyani Gary M. Vilke 《The Journal of emergency medicine》2018,54(4):571-575
Background
In 2010, the U.S. Food and Drug Administration (FDA) approved dabigatran as the first non-warfarin oral anticoagulant for use in the United States. At the time of FDA approval, there was no antidote or effective treatment for dabigatran-induced hemorrhage. In 2015, the FDA approved idarucizumab for the treatment of dabigatran-induced hemorrhage. The purpose of this clinical practice statement is to evaluate the role of select reversal agents in the management of patients with dabigatran-associated bleeding.Methods
A PubMed literature review was completed to identify studies that investigated the role of reversal agents in the management of emergency department patients with dabigatran-associated hemorrhage. Articles included were those published in the English language between January 2010 and January 2017, enrolled human subjects, and limited to the following types: randomized controlled trials, prospective trials, meta-analyses, and retrospective cohort studies. Review articles, case series, and case reports were not included in this review. All selected articles then underwent a structured review by the authors.Results
Six hundred fifty-two articles were identified in the search. After use of predetermined inclusion and exclusion criteria, six articles were selected for structured review.Conclusion
The clinical efficacy of activated prothrombin complex concentrates, idarucizumab, and recombinant factor VIIa remains unclear until further research is performed. Activated prothrombin complex concentrates, idarucizumab, and recombinant factor VIIa may be considered in patients with serious bleeding from dabigatran, after careful consideration of possible benefits and risks. 相似文献10.